---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002981"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:36:55.616715+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corvus Q1 net income $15.2M; soquelitinib atopic derm cohort 3 EASI −71.1% vs placebo −42.1%

## Summary
- Net income of $15.2M included $25.1M gain on warrant liability; R&D spend $7.5M vs $4.1M YoY.
- Cash $44.2M at Mar 31; May warrant exercises added ~$31.3M, extending runway into Q4 2026.
- Phase 1 atopic derm: cohort 3 (200 mg BID) achieved 71.1% mean EASI reduction vs 42.1% placebo; combined active vs placebo p=0.03.
- No placebo patient achieved IGA 0/1 or EASI 75; soquelitinib well tolerated with no DLTs.
- Protocol amended: replace cohort 4 with 24 patients (1:1 active/placebo) at 200 mg BID for 8 weeks; Phase 2 to start by year-end.

## SEC filing metadata
- accession: 0001171843-25-002981
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/0001171843-25-002981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/f8k_050825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002981
- JSON: https://secwatch.observer/filing/0001171843-25-002981.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.